CareDx (CDNA) Jumped 36% as Medicare Ended Its Three-Year Reimbursement War. What's Actually Priced In Before July 30?
Medicare's final LCD affirmed coverage above current utilization — one year after the draft that sank CDNA to $11. The balance-sheet math, the rate fine print bears will grab, and three scenario zones before July 30 earnings.
On Wednesday, the Centers for Medicare & Medicaid Services quietly published a document most of the market will never read: the final version of Local Coverage Determination L40060, "Molecular Testing for Solid Organ Allograft Rejection." CareDx (NASDAQ: CDNA) shareholders read it. The stock gapped from a $29.75 close to open at $36.40 and finished at $40.34 — up 35.6% on the day, a new 52-week high, on roughly six times normal volume.
To understand why a Medicare policy document is worth a third of a company's market value in a single session, you need the history — because this wasn't a one-day story. It was the final chapter of a three-year war over whether Medicare would keep paying for the blood tests that tell transplant patients if their new organ is being rejected.
The overhang that wouldn't die
CareDx's core business is non-invasive surveillance of transplanted organs. Its tests — AlloSure for kidney, heart, and lung; AlloMap for heart — detect donor-derived cell-free DNA in a recipient's blood. Rising levels signal the immune system is attacking the graft, often before a biopsy would catch it. AlloSure Kidney has been covered by Medicare since October 2017 under an LCD issued through Palmetto's MolDX program and adopted by Noridian, CareDx's Medicare contractor.
Then, in August 2023, MolDX and Noridian released a draft revision that read as a direct threat to routine surveillance testing — the recurring, scheduled use that makes up the economic core of the franchise. The stock spent the following year under a cloud. In August 2024, CMS blinked: the contractors announced they would not finalize the 2023 draft, explicitly affirming that transplant patients would keep access to surveillance testing while a new policy was drafted.
The reprieve lasted eleven months. On July 17, 2025, MolDX and Noridian published a new draft LCD — this time floating new coverage criteria, utilization limits, and a "bundled payment concept" that, in CareDx's own risk-factor language, "could lead to lower rates of reimbursement." By August 19, 2025, CDNA had been sold down to $11.26, its 52-week low. For three years, every valuation conversation about this company ended with the same asterisk: unless Medicare guts the reimbursement.
The final policy landed July 16, 2026 — 364 days after the draft, one day short of exactly a year. And it didn't gut anything.
What the final LCD actually says
The policy, effective August 30, 2026, affirms coverage across all three organs:
- Kidney: AlloSure Kidney covered for surveillance — up to 6 tests in the first year post-transplant, up to 4 per year in years two and three. For-cause testing unchanged.
- Heart: AlloMap and AlloSure Heart both covered, including combined use when medically appropriate — up to 12 surveillance tests in year one, 4 in years two and three.
- Lung: AlloSure Lung covered — up to 12 tests in year one, 4 in years two and three.
Here is the detail that matters for the revenue math: CareDx says AlloSure Kidney patients currently receive an average of roughly three to four tests in their first year. The new ceiling is six. The policy that was supposed to be the bear case finalized above current utilization. That's not survival — that's headroom.
The company underneath changed while everyone watched the courtroom
What makes Wednesday's repricing more than a relief bounce is what happened to the business during the three years the overhang suppressed the multiple. In the first quarter of 2026, CareDx posted $117.7 million in revenue, up 39% year over year, with testing services up 48% to $91.4 million on roughly 54,900 tests. It swung to GAAP profitability — $2.8 million of net income against a $10.4 million loss a year earlier. And in a ten-week span this spring, management executed a full portfolio rotation: agreed to divest the lab products business to Eurobio Scientific for $170 million in cash, closed the acquisition of Naveris — a Medicare-reimbursed cancer-recurrence testing business — on July 1, and authorized a $100 million buyback on a share count that is already lower than it was a year ago.
The reimbursement war is over. The question the market has to answer in the next nine trading days — Q2 earnings land after the close on July 30 — is what a debt-free, newly profitable diagnostics company growing testing revenue at 48% is worth once you delete the asterisk. After a 36% one-day repricing, how much of that answer is already in the stock — and what are the levels where the remaining scenarios play out?
The rest of this briefing is for paid members: the fine print in the final policy that bears will grab first (and how much revenue it actually touches), the balance-sheet math after the Naveris and Eurobio deals settle, the July 30 guidance setup, and three scenario price zones for where CDNA trades from here.
AlphaBriefing Paid gets you every investment thesis, scenario framework, and catalyst brief we publish — the analysis private intel clients pay four figures for, at a fraction of that.